Procedures
Cancer
ADVERSE EVENT, ADVERSE EVENT, CANCER
Patients received serplulimab or placebo (3 mg kgTumor imaging was scheduled once every 6 weeks for 48 weeks from randomization and every 12 weeks thereafter. Response was assessed according to RECIST v1.1 by the blinded IRRC and the investigators locally. During follow-up, patients were contacted every 12 weeks to assess survival. Adverse events and laboratory abnormalities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (v.4.03). Additional details regarding the study treatments, including dose interruptions and modifications, are provided in the study protocol.